Determination of microRNA biomarkers from blood for the pre- and post-treatment monitoring of non-small cell lung cancer (NSCLC)

Recruiting

• Conditions: C34; Malignant neoplasm of bronchus and lung; R91; J44; Abnormal findings on diagnostic imaging of lung; Other chronic obstructive pulmonary disease

• Registration Number: DRKS00018992
• Lead Sponsor: Hummingbird Diagnostics GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-11-27
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

• Male or female patient 50-80 years
• Patients suspicious to lung carcinoma (NSCLC) stage I and II or patients by whome the malignancy was excluded after resection (control group 2, for example benign lung disease) or patients with a lung disease (control group 3, eg COPD patients)
• Sufficient knowledge of German and the willingness to participate in the study

Exclusion Criteria

• known active infectious diseases (HIV, HCV, HBV)
• Neoadjuvant therapy or invasive diagnostics
• cancer in the last 5 years (except locally treated skin carcinoma - not malignant melanoma or prostate cancer)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ongitudinal analysis of microRNA biomarkers before and after resection of a curatively targeted localized non-small cell lung carcinoma (T1 / T2 / T3-N0-M0)

Secondary Outcome Measures

Name	Time	Method
Pre- and post-operation comparison of miRNA profiles for the diagnosis of minimal residual disease.